Understanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies

Similar documents
Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

Understanding How the U.S. Preventive Services Task Force Works USPSTF 101

U.S. Preventive Services Task Force Methods and Processes. Alex R. Kemper, MD, MPH, MS June 16, 2014

Foreword. Together, we can work to improve the health of all Americans. Albert L. Siu, M.D., M.S.P.H., Chair, U.S. Preventive Services Task Force

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE

Conflict of Interest Policy

INOVIO PHARMACEUTICALS, INC. INVESTIGATOR CONFLICT OF INTEREST POLICY

Request for Proposals

U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017)

4. Project Inform does receive restricted donations from corporations, non-profits, foundations, and government entities.

DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality

Policy of Conflict of Interest in Clinical Research

Paying for Routine HIV Testing

Disclosure Slide. Example 1:

Standards for Commercial Support SM : Standards to Ensure Independence in CME Activities

Community Benefits and the New Form 990

HICPAC Recommendation Categorization Update Workgroup: Public Comment Summary and Finalization

2018 AFP INTERNATIONAL COMMITTEE DESCRIPTIONS

Conflicts of Interest and Entrepreneurship

PLWH/A Consumer Participation: HRSA/HAB Expectations and Best Practices

Fiscal Year 2019 (July 1, 2018 June 30, 2019) Membership Information & Application

Gavi Alliance Conflict of Interest Policy Version 2.0

Ethical Practice Guidelines on Financial Incentives from Hearing Instrument Manufacturers

ACCME Performance in Practice Structured Abstract A tool for preparing and demonstrating compliance through performance in practice

The mission of AIGA is to advance designing as a professional craft, strategic tool and vital cultural force. Mission statement

Oral Presentation to the H.E.L.P. Committee on February 14, 2012 Philip A. Pizzo, MD

BC Confederation of Parent Advisory Councils

US Preventive Services Task Force : Who we are, What we do, and How we hope to work with you

CDC Guideline for Prescribing Opioids for Chronic Pain for Primary Care Providers

Statement in support of nomination for election to the Cochrane Board Fergus Macbeth MA DM FRCR FRCP MBA

RO-ILS: Radiation Oncology Incident Learning System Congressional Briefing

Duchenne Therapy Reviews on the Horizon. The FDA Advisory Committee Meetings. September 2, Host: Pat Furlong, PPMD President & Founder

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

January To: All Local CRN CHAPTERS

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.

Overcoming Structural Barriers to HIV Prevention

Improving Patient Care Through Education, Communication, and Research AMERICAN COLLEGE OF CHEST PHYSICIANS. David D. Gutterman, MD, FCCP

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

Title: Experimental evaluation of a parent-implemented AAC intervention protocol for children with severe autism

12 STEP RECOVERY AND FEMINIST, LGBTQ, AND ATHEIST POPULATIONS Rev. Eyglo Bjarnadottir Spiritual Care Addiction Treatment Professionals (SCATP)

Frequently Asked Questions about APIC s Potential Name Change to: Association for the Prevention of Infection

U.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults

Paul Appelbaum, Julio Arboleda-Flórez, Afzal Javed, Constantin Soldatos, Sam Tyano. WPA Standing Committee on Ethics

REGIONAL SPECIALIZED GERIATRIC SERVICES GOVERNANCE AUTHORITY. Call for Expressions of Interest from Seniors Advocate/Public Member

SCREENING FOR IPV BY HEALTH CARE PROVIDERS: FVPSA RESPONSE

The American Society of Echocardiography. Professional Benefits - Your Performance Stands Out, So Should You!

Access by pharmaceutical representatives

Psychodynamic Psychiatry and the Difficult Patient

Stay, Hit, or Fold? What Do You Do If the Treatment May Be as Bad as the Problem Results of a Q-PULSE Survey

Illinois Supreme Court. Language Access Policy

Wednesday, June 22, 2016

Information Package. Director Quit Tasmania Permanent full time (76 hours per f/n, three year contract)

Updates from the CDC Pediatric mtbi Guideline

Nitin S. Damle, Disclosure of Interests American College of Physicians

Myanmar national study on the socioeconomic impact of HIV on households

A resident's salary will continue, during the time they are exercising the Grievance Procedure rights, by requesting and proceeding with a hearing.

ACIP Developing Vaccine Recommendations and Policy in the US

The Oncofertility Consortium : Policy and Guidelines Statement

Lia Hotchkiss: I'm Lia Hotchkiss and I'm with the Agency for Healthcare. Research and Quality. We are one of the 12 agencies part of the Department of

QUALITY REVIEW PROGRAM REVIEW OF FORENSIC ACCOUNTING ENGAGEMENT QUESTIONNAIRE

Supplementary Online Content

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

The Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved

EVMS Authorship Guidelines

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Prescribing Opioids for Chronic Pain

Code of Practice on Authorship

Election of new internal members of the Cochrane Governing Board

Minnesota Administrative Uniformity Committee (AUC) Mission Statement, History and Governing Principles. June 2014

THE CARDIFF COMMITMENT TO YOUTH ENGAGEMENT AND PROGRESSION: REPORT OF DIRECTOR OF EDUCATION & LIFELONG LEARNING

Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and

Homeless Bound? Plenary 2: Working in partnership. Chief Executive East Thames Group Cllr Peter Fleming Leader Sevenoaks District Council

Business Impact Analysis

Policies, Procedures and Guidelines

NCCN Clinical Practice Guidelines Development Process

LOCAL EQUALITY ADVISORY FORUM (LEAF) A Staffordshire CCGs Equality & Inclusion Group. Terms of Reference

ELECTIONS APPLICATION FORM WPHNA Executive Committee

Integrated Care Approach to Chronic Pain. David Charles, MD

Powys teaching Health Board. Local Healthcare Professionals Forum. Terms of Reference - DRAFT

License to Ill: Playing the Odds After Withdrawing and Restarting Antiepileptic Drugs

HRSA TECHNICAL ASSISTANCE (TA) OUTREACH INITIATIVE

National Alzheimer s project U.S.

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

A Purchaser s Guide to Clinical Preventive Services: Moving Science into Coverage

EHR Developer Code of Conduct Frequently Asked Questions

Background USPSTF Guideline

Secretary's Advisory Committee on Heritable Disorders in Newborns and Children May 13, 2009

Controversies in Breast Cancer Screening Strategies. Breast Cancer Screening Guidelines

Nebraska Diabetes Prevention Action Plan

2/12/2016. Disclosure. Objectives. The Hospice Medical Director: What Should They Be Doing?

Comms. Present: Comms. DeYoung, Greenfield, Hirt, McLaughlin, Pilcher & Snyder (Comm. Butler excused) Medical Staff Leadership:

CMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.

Tuesday, June 23, 2015

Emerge Leadership Team Volunteer Application

Ultrasound Guided Vascular Access March 22, 2018

UCLH Cancer Collaborative Patient Experience and User Involvement Steering Group Member s Role Description: People affected by cancer

REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition

Thank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements

Transcription:

1 Understanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies Quyen Ngo-Metzger, MD, MPH Scientific Director, USPSTF Program Agency for Healthcare Research and Quality October 17, 2016

2 Overview The U.S. Preventive Services Task Force Is an independent panel of non-federal experts in prevention & evidence-based medicine Makes evidence-based recommendations about clinical preventive services, including screening, counseling, and preventive medications Recommendations address only services offered in the primary care setting or services referred by a primary care clinician. Recommendations apply to adults & children with no signs or symptoms (or unrecognized signs and symptoms)

3 Overview The U.S. Preventive Services Task Force Makes recommendations based on rigorous review of existing peerreviewed evidence Does not conduct the research studies, but reviews & assesses the research Evaluates benefits & harms of each service based on factors such as age & sex

4 USPSTF Members The 16 volunteer members represent disciplines of primary care including family medicine, internal medicine, nursing, obstetrics/gynecology, pediatrics, and behavioral medicine Led by a Chair & Vice Chairs Serve 4-year terms Appointed by AHRQ Director with guidance from Chair & Vice Chairs Undergo a rigorous review of potential conflicts of interest Current members include deans, medical directors, practicing clinicians, and professors www.uspreventiveservicestaskforce.org/members.htm

5 AHRQ s Support of the Task Force AHRQ, an agency within the U.S. Department of Health and Human Services (HHS), provides administrative, scientific, technical, and dissemination support to the USPSTF AHRQ s Mission: to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within HHS and with other partners to make sure that the evidence is understood and used While AHRQ provides support to the USPSTF, it is important to note that the USPSTF is an independent entity

6 USPSTF Recommendation Development Process Rigorous 4-stage recommendation development process: Topic nomination Draft and final research plans Draft evidence review and recommendation statement Final evidence review and recommendation statement 4-week public comment period on all draft materials The Task Force works with AHRQ Evidence-based Practice Centers (EPCs) to develop research plans and review evidence Subject matter experts are consulted throughout the recommendation development process Procedure Manual available under Methods and Processes at: www.uspreventiveservicestaskforce.org

USPSTF Conflicts of Interest Policies 7 USPSTF requires each member to disclose any real or perceived financial and non-financial conflict(s) of interest for self, immediate family members, and close personal relationships. Financial conflicts include stocks, equity positions, consulting agreements, employment arrangements, or research grants/contracts, and travel reimbursement and honorariums sponsored by industry, advocacy or professional organizations. Non-financial conflicts include public comments and testimony, leadership role on a panel, substantial career efforts/interests, previously published opinions, and advocacy or policy positions.

8 Potential Financial Conflicts of Interest Task Force members report all financial relationships regardless of amount. Ownership of individual stocks (shares, options, warrants), and bonds or other debt or other significant proprietary interests or investments in any third party that could be affected by a USPSTF decision on a specific topic Having an employment, independent contractor or consulting relationship with an entity that could be financially or reputationally affected by a Task Force decision Receiving a proprietary research grant or receiving patents, royalties or licensing fees from such an entity

9 Potential Financial Conflicts of Interest Participating on an entity s proprietary governing board or advisory council Participating in an entity s speakers bureaus Receiving honoraria or travel from such an entity Receiving payment as an expert witness for a plaintiff or a defendant associated with such an entity Receiving remuneration for services with respect to transactions involving parties with a financial interest in the outcome of a USPSTF decision. This may include clinical specialty practice.

Potential Non-Financial Conflicts of Interest 10 Could be numerous because Task Force members are chosen for their national reputations on prevention issues and their work may be very well-known Users of Task Force products might doubt the objectivity of the process if such members are known to have taken leadership roles in discussion and vote on recommendations regarding that topic. Goal: to disclose and mitigate potential bias

11 Potential Non-Financial Conflicts of Interest Required to disclose substantial non-financial interests including: Public comments and testimony Leadership role on a panel Substantial career efforts/interests in a single area Previously published opinions Advocacy or policy positions

Process for Determining Appropriate Actions 12 Prior to new member appointment and assignment on topics, all disclosures are reviewed by AHRQ and the Task Force Chairs according to the criteria specified in the USPSTF Procedure Manual and determined to be either Level 1, 2, or 3. Task Force Chairs determine the final action on the member's eligibility to participate on a specific topic based on the nature and significance of the potential COI.

Process for Determining Appropriate Actions 13 Level 1 disclosures include nonfinancial disclosures that would not affect the judgment of a Task Force member. These disclosures do not require any action. Level 2 disclosures include financial disclosures of $1,000 or less and nonfinancial disclosures that are relevant to a topic but not anticipated to affect the judgment of the Task Force member for that topic. These disclosures are announced at the Task Force meeting, but do not limit the Task Force member s participation in the topic process.

Process for Determining Appropriate Actions Level 3 disclosures: Financial disclosures of a larger amount and significant nonfinancial disclosures that may affect the Task Force member's view on the topic. Actions for Level 3 disclosures vary according to the nature of the conflict, and may include preventing the member from serving on the workgroup of a topic, serving as a primary spokesperson for a topic, or preventing the member from taking part in all topic activities including voting. As all new Task Force members are reviewed for conflicts prior to joining, Level 3 disclosures are rare. 14

Thank you for your interest www.uspreventiveservicestaskforce.org 15